Pharmalot… Pharmalittle… Good Morning
Make a commentBy Ed Silverman // September 23rd, 2010 // 7:03 am
Good morning, folks. Another shiny day is emerging as we hustle the short people off to the local schoolhouse and busy ourselves with the news of the world. Speaking of which, the House passed a bill that would ban corporate execs from doing business with Medicare and Medicaid if their companies were convicted of fraud (take a peek). Now, though, the time has come for a cup of stimulation. Please join us, and have a great day…
Merck Will Review Planned Facility Closing (Radio Netherlands)
Perils For Pill Pushers (The Financial Times)
Abbott Buys Rights To Kidney Drug (The Wall Street Journal)
FDA Finds Risk In Glaxo Rotarix Vaccine Data (Reuters)
European Parliament Endorses Drug Monitoring Rules (PharmaTimes)
Clinical Trials In Russia & Eastern Europe Fell In 2009 (OutsourcingPharma)
Fake Avastin Hurts 61 People (Shanghai Daily)
Abbott Recalls Baby Formula Tainted With Beetles (Reuters)
Funding Row Leaves Welsh Cancer Patients Without Drug (PharmaTimes)
Leave a Comment
Subscribe
Comments feed for this post only.
Tags
Abbott Laboratories, Avandia, Avastin, Baby Formula, Birth Control, Cancer, Clinical Trials, GlaxoSmithKline, jobs, Johnson & Johnson, Merck, Ortho Evra, Roche, Rotarix, Russia, The Netherlands, Wales